About this trial
This is a Phase III clinical randomized control trial to investigate differences between patient with an infected nonunion treated by PO vs. IV antibiotics. The study population will be 250 patients, 18 years or older, being treated for infected nonunion after internal fixation of a fracture with a segmental defect less than one centimeter. Patients will be randomly assigned to either the treatment (group 1) PO antibiotics for 6 weeks or the control group (group 2) IV antibiotics for 6 weeks. The primary hypothesis is that the effectiveness of oral antibiotic therapy is equivalent to traditional intravenous antibiotic therapy for the treatment of infected nonunion after fracture internal fixation, when such therapy is combined with appropriate surgical management. Clinical effectiveness will be measured as the primary outcome as the number of secondary re-admissions related to injury and secondary outcomes of treatment failure (re-infection, nonunion, antibiotic complications) within the first one year of follow-up, as defined by specified criteria and determined by a blinded data assessment panel. In addition, treatment compliance, the cost of treatment, the number of surgeries required, the type and incidence of complications, and the duration of hospitalization will be measured.
Eligibility criteria
Qualifiers
1. Bone fracture (proximal to and including the tarsal/metatarsal joint (Lisfranc) or proximal to the carpal joints (includes distal radius fractures), excluding pelvis and spine) that has previously undergone fixation and has not healed and requires fixation to be retained or replaced at least until bone union. Fractures that have not healed and require revision fixation are also eligible.
Infection as determined by either
FRI criteria
CDC criteria (without the timeframe) This includes the possibility of culture negative, but determined to be infection by treating surgeon
Disqualifiers
Patients with a high risk of amputation based on the initial managing physician
Patients undergoing treatment of any other investigational therapy within the month preceding infection treatment or planned within the 12 months following infection treatment
Incarcerated or institutionalized patients
Patients who are unable to return for required follow-up visits and/or medical co-morbidities which preclude treatment with a general anesthetic
Trial design
Treatments tested in this trial
- Standard of Care PO (oral) antibiotics
- Standard of Care Intravenous (IV) antibiotics
Treatment groups
Sponsors and collaborators
Major Extremity Trauma Research Consortium
Lead sponsor
United States Department of Defense
Collaborator